Clinical trial · people

Tesamorelin: model accurately predicted GH and IGF-1 over 14 days

Checked against the paper Clinical trialPublished by PepVault

The takeaway

In early short trials, GH and IGF-1 levels on daily tesamorelin followed a predictable pattern, and none of the traits checked, including HIV status, showed a significant link to it.

Kind
Clinical trial
Studied in
People
Number studied
41
Published
2015
Journal
J Pharmacokinet Pharmacodyn

What they tested

The team wanted to map how growth hormone (GH) and insulin-like growth factor (IGF-1) levels change over time with daily tesamorelin, and whether traits like age, weight or HIV status were linked to that pattern.

How the study was done

A modeling analysis that pooled Phase I trials covering 41 people with HIV or healthy volunteers, each given a daily under-the-skin dose of 1 or 2 mg of tesamorelin for 14 days in a row. The team built a model of GH and then IGF-1 levels, starting from an earlier model of tesamorelin blood levels.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

Model. Individual results vary.

PepVault for iPhone

Taking tesamorelin? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

The model accurately predicted GH and IGF-1 levels over time after repeated tesamorelin doses. It passed checks that compare predictions with real data and that resample the data many times. Within the range of values studied, none of age, body weight, body mass index, sex, race or health status (HIV or healthy) was significantly linked to the GH or IGF-1 model results.

What it doesn’t show

The model was built from 41 people in Phase I trials over 14 days and tracked only GH and IGF-1 levels. The results on age, weight, sex, race and HIV status hold only within the range of values evaluated.

The paper

González-Sales et al. Population pharmacokinetic and pharmacodynamic analysis of tesamorelin in HIV-infected patients and healthy subjects. J Pharmacokinet Pharmacodyn. 2015.

The compound

More studies on Tesamorelin

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking tesamorelin? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo